Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) is advancing its lead oncology candidate, ONC010, a PNKP inhibitor designed to disrupt cancer cells' DNA repair mechanisms and potentially overcome treatment resistance. The company recently completed kilogram-scale manufacturing of a key precursor for ONC010's active pharmaceutical ingredient, a critical step toward formulation development, GMP production, and future clinical studies.
To support these efforts, Onco-Innovations signed a letter of intent with Nanosoft Polymers to collaborate on polymer development, drug delivery optimization, and formulation work. Additionally, the company has engaged Nucro-Technics and Avance Clinical for bioanalytical development and clinical and regulatory planning. These partnerships are part of a broader strategy to build the manufacturing, formulation, and clinical infrastructure necessary to advance ONC010 toward first-in-human studies.
ONC010 targets the DNA repair enzyme polynucleotide kinase/phosphatase (PNKP), which is often overactive in cancer cells, enabling them to repair DNA damage and resist treatment. By inhibiting PNKP, ONC010 may sensitize tumors to chemotherapy and radiation, offering a new approach for patients with resistant cancers. The company's progress in scaling up manufacturing and securing expert partners underscores its commitment to bringing this novel therapy to the clinic.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, with an exclusive worldwide license to patented technology targeting solid tumors. For more information, visit https://oncoinnovations.com/. The latest news and updates are available in the company's newsroom at https://ibn.fm/ONNVF.
